💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mangafodipir Trisodium

CHEMBL2096651 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
757.3 g/mol
LogP
—
Phase
4

A trisodium form of mangafodipir with the same therapeutic properties. A manganese-based contrast agent previously used during MRI scans to enhance the visibility of liver and pancreatic lesions, helping to distinguish tumors from normal tissue.

Peso molecular

757,3000 g/mol

TPSA

303,00 Ų

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Diabetes tipo 2 Enfermedad renal crónica Epilepsia Esclerosis múltiple Insuficiencia cardíaca

Mecanismo de acción

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
[H+].[H+].[H+].CC1=NC=C(C(=C1[O-])CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)[O-])CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Mn+2]

                

                

                
                

                    
InChI

                    
InChI=1S/C22H32N4O14P2.Mn.3Na/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32;;;;/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);;;;/q;+2;3*+1/p-5

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H27MnN4Na3O14P2

                    

                    
                    

                        
HBD / HBA

                        
3 / 18

                    

                    
                    

                        
Enlaces Rotables

                        
13

                    

                    
                    
                    

                        
Átomos Pesados

                        
46

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A trisodium form of mangafodipir with the same therapeutic properties. A manganese-based contrast agent previously used during MRI scans to enhance the visibility of liver and pancreatic lesions, helping to distinguish tumors from normal tissue.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mangafodipir Trisodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2096651.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 160036.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.